Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2017 year
    12
    12 day
    Ipsen China and Zhejiang Medical announced conclusion of strategic cooperation agreement

    (Hangzhou, Zhejiang, China)-On December 12, 2017, Bofu-Ipsen (Tianjin) Pharmaceutical Co., Ltd. (hereinafter referred to as 'Ipsen China') and Zhejiang Medical Technology Development Co., Ltd. (hereinafter referred to as 'Zhejiang Medical') announced today that they had formally concluded a strategic cooperation agreement to promote Tanakan® in the Chinese market. 


    Ipsen China and Zhejiang Medical announced conclusion of strategic cooperation agreement


    This strategic cooperation is the beginning of mutual complementarity, information sharing and mutual benefit. With the signing of the strategic cooperation agreement, the two sides will further expand the scope of cooperation in marketing and promotion, brand building, customer service and other aspects, strengthen the content of cooperation, enhance the value of cooperation, and bring effective benefits to patients. 


    Ipsen China and Zhejiang Medical announced conclusion of strategic cooperation agreement


    'Zhejiang Medical has been committed to bringing more added value to Chinese patients and doctors, and has a mature academic promotion system and an efficient operation and management system. We are very honored to establish a cooperative partnership with Zhejiang Medical. I believe the cooperation between the two sides will bring a healthier development and a good reputation to Tanakan®. ' Mr. Chen Jialin, general manager of Ipsen China, said, 'As far as Ipsen Group is concerned, we focus on tumor, neuroscience and rare diseases, etc. In 2017, the global business maintained a double-digit growth, especially reaching 22.6% in the third quarter. Meanwhile, in the current research and development lines of the group, there are also a number of products related to tumor treatment, with very promising research and development prospects. In the Chinese market, Ipsen has returned to a double-digit growth this year. As of September, Ipsen has achieved a year-on-year growth of 14.2% and achieved a 26% growth rate in retail channels. Specifically, Smecta® has achieved remarkable results and obtained the highest market share in the past five years. Based on the good development momentum of business and the concern for research and development, I have great confidence in the continuous and in-depth development of Zhejiang Medical in the future. ' 


    Mr. Wang Wei, president of Zhejiang Medical, pointed out: 'Tanakan® is an imported high-quality ginkgo leaf preparation. Its unique extraction process not only lays a good foundation for product safety, but also brings effective solutions to patients. Meanwhile, the current situation of China's aging population further brings opportunities to the sales of Tanakan®. We are very honored to be able to establish a strategic cooperation relationship with Ipsen China, which will ultimately bring benefits to the vast number of Chinese patients. ' 


    On the basis of mutual benefit and win-win cooperation, this strategic cooperation between Ipsen China and Zhejiang Medical is expected to bring forth the optimal combination of strength of both sides, and lay a good foundation for further development of the future partnership.

     

    About Ipsen China 


    Ipsen Group is an international pharmaceutical company headquartered in France, and focuses on specialized disease treatment. Its total sales in 2016 exceeded 1.6 billion euros. Ipsen Group has more than 20 kinds of products. Its sales network covers 115 countries, and it has directly established commercial companies in 30 of them. Ipsen Group has been committed to becoming a leader in providing professional therapeutic regimens in the target disease areas, whose business development strategy is supported by three target disease areas, namely, tumor, neuroscience and rare diseases. The group also has outstanding performance in the field of general practice diseases, mainly gastrointestinal diseases. Ipsen Group has always centered on research and development. In 2016, its research input accounted for about 13% of the group's sales. Its three R & D centers are located in Paris-Thackeray in France, Oxford in the UK and Cambridge in the USA. Ipsen entered the Chinese market in 1992, with its headquarters of the Greater China Region in Beijing, and has a factory in Tianjin. Its products sold in China include Smecta®, Triptorelin®, Etiasa®, Forlax®, Fortrans®, and Somadulin®. 

     

    About Zhejiang Medical 


    Zhejiang Medical Technology Development Co., Ltd. is a holding subsidiary of Hongkong Winhealth Pharma Group Co., Ltd . Since its establishment, it has always adhered to the corporate objective of 'safeguard life and health and enjoy peace of life', committed to introducing the world's leading health products and medical technologies into the Chinese market, and has formed long-term strategic cooperation with many well-known pharmaceutical enterprises at home and abroad in many fields such as respiration, anti-infection, cardiovascular and cerebrovascular diseases, urological diseases and hematological tumors. After years of unremitting efforts, it has developed into a professional third-party medical service company capable of providing registration, import, distribution and promotion of drugs and medical devices, with a network covering more than 30 provinces and cities and more than 6,000 medical institutions.

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.